FULC Company Profile and Key Details

Q: Who are the executives of FULC?

Prof. Jeannie T. Lee M.D., Ph.D.FounderMr. Alexander C. SapirChief Executive Officer, Pres & DirectorDr. Jeffrey W. Jacobs Ph.D.Chief Scientific OfficerDr. Bradley E. Bernstein M.D., Ph.D.FounderMr. Bryan E. StuartPres, Chief Executive Officer & DirectorMr. Mel HayesChief Operating OfficerDr. Judith A. Dunn Ph.D.Interim Chief Medical OfficerMr. Gregory TourangeauController & Principal Accounting OfficerMs. Esther P. RajaveluChief Financial Officer & TreasurerDr. Rudolf Jaenisch M.D., Ph.D.FounderDr. Michael R. GreenFounderMr. Alan A. Musso C.M.A., C.P.A., CPAChief Financial OfficerDr. Danny ReinbergFounderMr. Alan A. Musso C.M.A., CPA, CPAChief Financial OfficerDr. Robert J. Gould Ph.D.Pres, Interim Chief Executive Officer & DirectorMr. Curtis G. Oltmans J.D.Senior Vice President, Chief Legal Officer & Corporation Sec.

NASDAQ : FULC

Fulcrum Therapeutics

$8.02

0.08+1.01%

Open: 10:43 AM

59.51

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Fulcrum Therapeutics, Inc. (FULC) stock surged +1.01%, trading at $8.02 on NASDAQ, up from the previous close of $7.94. The stock opened at $8.11, fluctuating between $7.94 and $8.19 in the recent session.

Stock Snapshot

7.94

Prev. Close

433.97M

Market Cap

7.94

Day Low

-6.8

P/E Ratio

-1.18

EPS (TTM)

-1.48

Cash Flow per Share

8.11

Open

54.11M

Number of Shares

8.185

Day High

88.64%

Free Float in %

3.8

Book Value

108.55K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Mar 09, 2026	7.82	8.11	7.59	7.94	1.02M
Mar 06, 2026	8.04	8.45	7.95	8.17	767.29K
Mar 03, 2026	7.67	8.40	7.58	7.87	1.61M
Mar 02, 2026	8.17	8.26	7.52	7.81	3.56M
Feb 27, 2026	8.68	8.84	8.25	8.38	758.84K
Feb 26, 2026	8.91	9.04	8.64	8.73	803.48K
Feb 25, 2026	8.36	9.34	8.33	8.98	2.23M
Feb 24, 2026	9.65	10.42	8.49	8.58	4.16M
Feb 23, 2026	11.08	11.39	10.58	10.89	1.12M
Feb 20, 2026	11.59	11.89	10.95	11.00	817.02K
Feb 19, 2026	10.83	12.03	10.83	11.73	1.06M
Feb 18, 2026	10.69	11.50	10.69	10.94	622.84K
Feb 17, 2026	10.51	10.82	10.25	10.66	810.52K
Feb 13, 2026	10.82	11.17	10.62	10.63	367.24K
Feb 12, 2026	10.88	11.09	10.46	10.86	462.48K
Feb 11, 2026	10.36	10.87	10.04	10.87	855.8K
Feb 10, 2026	10.13	10.51	10.07	10.34	446.29K
Feb 09, 2026	9.78	10.33	9.37	10.23	394.09K
Feb 06, 2026	9.71	10.00	9.62	9.74	489.2K
Feb 05, 2026	9.85	10.51	9.52	9.55	432.51K

Contact Details

Cambridge, MA 02139

United States

https://www.fulcrumtx.com 617 651 8851

About Company

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy; and FTX-6058, an investigational oral fetal hemoglobin inducer for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has research and discovery collaboration agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and has a strategic collaboration and license agreement with MyoKardia, Inc. to discover, develop, and commercialize novel targeted therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Stock Peers

REGN

21.74+2.86%

Regeneron Pharmaceuticals, Inc.$781.60 ARGX

22.6+3.15%

argenx SE$740.40 UTHR

51.01+10.67%

United Therapeutics Corporation$529.17 VRTX

4.18+0.92%

Vertex Pharmaceuticals Incorporated$460.87 MDGL

0.37+0.09%

Madrigal Pharmaceuticals, Inc.$433.20 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 ALNY

2.93+0.91%

Alnylam Pharmaceuticals, Inc.$323.59 PRAX

-1.7-0.55%

Praxis Precision Medicines, Inc.$309.01 KRYS

4.96+1.96%

Krystal Biotech, Inc.$258.65 ASND

-0.73-0.30%

Ascendis Pharma A/S$239.92

Company Overview

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) closed at $8.02 USD, gaining $0.08 (1.01%) from the previous close of $7.94. The stock is currently mid-range between its 52-week high and low $2.31 and $15.74. With a market capitalization of about $433.97 million, Fulcrum Therapeutics, Inc. is classified as a small-cap and shows higher-than-market volatility (beta ~3.29). Key stats such as the average daily volume over the past year has been around 982.66 thousand shares, volume is running light vs its 52-week average. Headquartered in Cambridge, MA, Fulcrum Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Alexander C. Sapir, the company employs approximately 45 people and listed since July 18, 2019. Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States.

Technical Performance

FULC has shown sold momentum, gaining 11.46% over the past week and 17.91% over the past quarter, though year-to-date performance is down -6.28%. Short-term trend indicators are mixed aligned (SMA20 -15.45%, SMA50 -18.98%, SMA200 0.48%). The stock’s 14-day RSI is 36.56 (weak momentum), while the ATR of 0.86 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -44.54% below its high and over 277.11% above its low. Average 10-day trading volume of 1.74 million shares is significantly above the 3-month average of 1.03 million, indicating heightened recent market interest.

Valuation Metrics

Fulcrum Therapeutics, Inc. trades at a P/E ratio of -6.52, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 1.4 suggesting the stock is closer to book value. The P/FCF stands at -6.91, also above market averages.

Dividend & Fair Value

Fulcrum Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $3.02. This means the shares are trading above this model’s fair value.

Earnings & Analyst Outlook

Fulcrum Therapeutics, Inc. generated EPS of -$1.18 over the past year. Five-year average earnings growth is 15.8%. Wall Street analysts project EPS growth of 5.16% annually over the next five years. The latest quarter delivered EPS of -$0.31. The next quarter is forecast at -$0.30. Next year's EPS is expected at -$9.67. Analyst sentiment is bullish. Analyst rating data shows there are 3 Strong Buy ratings, 6 Buy ratings, 3 Hold ratings, 0 Sell rating and 1 Strong Sell ratings. Price targets range from $25.00 to $5.00. The high target offers 214.86% upside. The low target suggests -37.03% downside. The mean target is $14.69. This offers 85.01% upside. Fulcrum Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended October 29, 2025, missed forecasts by 7.94%. The prior quarter beat by -3.45%. Over the last six quarters, Apple has recorded several small beats. These include -1551.67% in July 31, 2024.

Shareholding & Insider Activity

Fulcrum Therapeutics, Inc. has 54.09 million shares outstanding. The public float is 14.59 million shares, elevated short interest at 13.40% of float. This equals 5.02 million shares. The short ratio is 5.37 days. Institutional investors hold 103.43% of the float. Insiders own 1.82%. RA CAPITAL MANAGEMENT, L.P. holds 6.05 million shares, LEVIN MARK J has 5.96 million shares and Third Rock Ventures III, L.P. has 5.96 million shares. Over the past six months, insider transactions show net selling. They sold 140.17 thousand shares across 5 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Fulcrum Therapeutics generated $2.81M in revenue, or $0.05 per share. Gross margin was 22.57%, operating margin -3945.24%, and net profit margin -3470.05%. Returns are negative, with ROA at -37.77% and ROE at -41.39%.
On valuation metrics, Fulcrum Therapeutics trades at a P/E of -6.52, P/S of 0.00 and P/B of 1.40. The current ratio is 27.40 and quick ratio is 27.40. Debt-to-equity is 0.02, supported by a cash flow-to-debt ratio of -9.32.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Fulcrum Therapeutics posted revenue of $2.81M, down slightly from $6.34M in the prior quarter. Gross profit was $633.00K (margin 22.57%). Operating income was - $110.66M (margin -3945.2%). Net income was- $97.34M (EPS - $1.59).
The company ended the quarter with $236.22M in cash and short-term investments, a total debt of $10.82M, and net debt of - $14.74M. Total assets were $257.69M, with equity of $235.19M. Financials further reflected weakness, with operating cash flow of - $90.97M, free cash flow of - $91.47M, and capital expenditures of - $508.00K.

Price Forecast & Outlook

Our AI price prediction model suggests that Fulcrum Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -4.91%, with price expected at $7.55 by March 23, 2026, within a range of $6.54 to $8.60 3-Month Outlook: Projected rise of 294.96%, reaching $31.36 by June 05, 2026, with a range of $31.07 to $31.63. 1-Year Outlook: Projected gain of 238.79%, with price at $26.90 by March 09, 2027, within a range of $28.21 to $31.56.

Key Takeaways

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) shares are flat -6.28% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Fulcrum Therapeutics, Inc. trading at a premium to the broader market with a P/E of -6.52. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $15.06, suggesting 89.67% upside. Our AI forecast model points to short-term weakness (-4.91% over two weeks), a medium-term rise (294.96% over three months), and a longer-term gain (238.79% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Fulcrum Therapeutics, Inc. (FULC) stock price?

Fulcrum Therapeutics, Inc. (NASDAQ: FULC) stock price is $8.02 in the last trading session. During the trading session, FULC stock reached the peak price of $8.19 while $7.94 was the lowest point it dropped to. The percentage change in FULC stock occurred in the recent session was 1.01% while the dollar amount for the price change in FULC stock was $0.08.

FULC's industry and sector of operation?

The NASDAQ listed FULC is part of Biotechnology industry that operates in the broader Healthcare sector. Fulcrum Therapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of FULC?

Prof. Jeannie T. Lee M.D., Ph.D.
Founder
Mr. Alexander C. Sapir
Chief Executive Officer, Pres & Director
Dr. Jeffrey W. Jacobs Ph.D.
Chief Scientific Officer
Dr. Bradley E. Bernstein M.D., Ph.D.
Founder
Mr. Bryan E. Stuart
Pres, Chief Executive Officer & Director
Mr. Mel Hayes
Chief Operating Officer
Dr. Judith A. Dunn Ph.D.
Interim Chief Medical Officer
Mr. Gregory Tourangeau
Controller & Principal Accounting Officer
Ms. Esther P. Rajavelu
Chief Financial Officer & Treasurer
Dr. Rudolf Jaenisch M.D., Ph.D.
Founder
Dr. Michael R. Green
Founder
Mr. Alan A. Musso C.M.A., C.P.A., CPA
Chief Financial Officer
Dr. Danny Reinberg
Founder
Mr. Alan A. Musso C.M.A., CPA, CPA
Chief Financial Officer
Dr. Robert J. Gould Ph.D.
Pres, Interim Chief Executive Officer & Director
Mr. Curtis G. Oltmans J.D.
Senior Vice President, Chief Legal Officer & Corporation Sec.

How FULC did perform over past 52-week?

FULC's closing price is 242.98% higher than its 52-week low of $2.32 where as its distance from 52-week high of $15.74 is -49.55%.

How many employees does FULC have?

Number of FULC employees currently stands at 45.

Link for FULC official website?

Official Website of FULC is: https://www.fulcrumtx.com

How do I contact FULC?

FULC could be contacted at phone 617 651 8851 and can also be accessed through its website. FULC operates from 26 Landsdowne Street, Cambridge, MA 02139, United States.

How many shares of FULC are traded daily?

FULC stock volume for the day was 108.55K shares. The average number of FULC shares traded daily for last 3 months was 982.66K.

What is the market cap of FULC currently?

The market value of FULC currently stands at $433.97M with its latest stock price at $8.02 and 54.11M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	45
Beta	3.29
Sales or Revenue	$2.81M
5Y Sales Change%	0%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

FULC Company Profile and Key Details

Fulcrum Therapeutics

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Earnings & Analyst Outlook

Company Overview

Dividend & Fair Value

Price Forecast & Outlook

Key Takeaways

Valuation Metrics